DJIA 16,102.38 -272.38 -1.66%
NASDAQ 4,683.92 -49.58 -1.05%
S&P 500 1,921.22 -29.91 -1.53%
market minute promo

Regeneron Pharmaceuticals (NASDAQ: REGN)

499.99 -8.52 (-1.68%)

REAL-TIME: Last trade at

Extended Hours: $501.80 $1.73 (0.35%)
Quote as of (NASDAQ)



company name or ticker

Recent Quotes

REGN $499.99 -1.68%
Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $500.51
Previous Close $508.51
Daily Range $498.98 - $507.97
52-Week Range $320.06 - $605.93
Market Cap $51.8B
P/E Ratio 128.41
Dividend (Yield) $0.00 (0.0%)
Volume 806,525
Average Daily Volume 818,231
Current FY EPS $9.61

Sector

Healthcare

Industry

Drug Makers

Regeneron Pharmaceuticals (REGN) Description

The Company is a biopharmaceutical company that discovers, develops, and intends to commercialize pharmaceutical products for the treatment of serious medical conditions. Website: http://www.regeneron.com/

News & Commentary

PCSK9 Drugs Are Here (and Way Over There)

As the first generation of the cholesterol-lowering drugs hits the market, investors should already be looking at the next-generation products.

Roche's Hemophilia A Drug Gets Breakthrough Status in U.S.

Allergan (AGN) to Buy Eye Care Device Company AqueSys

The Zacks Analyst Blog Highlights: Google, Gilead Sciences, Regeneron Pharmaceuticals, Intuitive Sur

The Zacks Analyst Blog Highlights: Google, Gilead Sciences, Regeneron Pharmaceuticals, Intuitive Surgical and Amazon.com

3 Stocks Pushing The Drugs Industry Lower

Why Regeneron Pharmaceuticals (REGN) Could Be a Potential Winner

3 Stocks We're Watching In The Third Quarter

Here are three companies our analysts have their eyes on

Regeneron and Sanofi Present Encouraging Praluent Data

Illumina Acquires GenoLogics, Boosts Genomic Sequencing

Amgen's Next-Generation Cholesterol Drug Is Approved, but Pricing Is a Huge Concern

Repatha gets the green light from the Food and Drug Administration, but pharmacy benefit managers and insurers are ready to give PCSK9 inhibitors the red light.

See More REGN News...

REGN's Top Competitors

REGN $499.99 (-1.68%)
Current stock: REGN
GILD $102.06 (0.15%)
Current stock: GILD
AMGN $147.02 (-1.48%)
Current stock: AMGN
BIIB $302.26 (0.21%)
Current stock: BIIB